Skip to main content

Table 2 Renal parameters, immunoglobulin (Ig)A, IgG and IgM levels, and IgG course, Days-14 to 14

From: Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Patient
#
Screening day
(Day -14)*
Day 1 Day 14
  GFR UPr:Cr IgG GFR UPr:Cr IgA IgM IgG IgG change
from Day -14
GFR UPr:Cr IgA IgM IgG IgG change
from Day 1
  (ml/min/1.73 m 2 ) (mg/mg) (g/l) (ml/min/1.73 m 2 ) (mg/mg) (g/l) (g/l) (g/l)   (ml/min/1.73 m 2 ) (mg/mg) (g/l) (g/l) (g/l) (%)
2 73.5L 1.6 16.3 68.4L 0.2 1.9 1.0 16.3 0 45.3L1, a 0.1a 2.0a 0.8a 15.1a -7.4
8 78.7 2.3 14.2 76.3 N/A 2.9 0.3L 13.9 -2.1 88.8a 0.8a 2.7a 0.3L, a 11.1a -20.1
3 73.4L 8.2 16.3 81.6 5.6 4.5 1.2 13.0 -20.3 72.2L 8.1a 2.3a 0.7a 6.5a -49.7
5 74.5L 3.0 20.1 89.0 1.0 6.3 1.2 14.3 -28.9 69.7L, b 7.1 5.4 b 1.1b 10.9b -23.8
13 33.6L2 4.6 11.3 30.9L2 12.4 1.1 0.3L 4.9L -56.9 34.1L2, a 8.4a 0.6L, a < 0.2L 3.6L, a -25.5
14 26.9c,, L2 12.0 9.1 24.4L2 18.0 < 0.3L < 0.2L 4.8L -47.1 38.8L2, d 9.0d 0.5L, d 0.6d 2.5L, d -47.4
  1. Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). *IgA and IgM levels not recorded at screening; GFR, glomerular filtration rate; Ig, immunoglobulin; UPr:Cr, urine protein:creatinine ratio.
  2. Values > ULN indicated in italics; LValues < LLN with (Grade 1 to 4), where applicable; Ig reference ranges: IgA, 0.7 to 4.0 g/l; IgM, 0.4 to 2.3 g/l; IgG, 5.7 to 17.6 g/l. aMeasured Day 15; bMeasured Day 13; cMeasured Day -18; dMeasured Day 18. †GFR > 30 ml/min/1.73 m2 on repeat testing.